Clinical Trial

Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma \*To evaluate best objective response rate (ORR)
Trial Details
NCT Number NCT07709624
Lead Sponsor TTY Biopharm
Conditions DLBCL
Enrollment 50 participants
Start Date 2025-12-01
Primary Completion 2030-01-28 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-16